Evidence map›Paper›PMID 36651624›Full record

Trial reportThe American journal of psychiatry2023

Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy.

Boadie W Dunlop, Jungho Cha, Ki Sueng Choi, Justin K Rajendra, Charles B Nemeroff, W Edward Craighead, Helen S Mayberg

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Psychotherapy and inhibitory control: Insights from fMRI research.Psychiatry and clinical neurosciences · 2026
    Pooled it
  2. Trial
  3. Trial
  4. Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Boadie W DunlopDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, Craighead); Department of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Cha, Choi, Mayberg); Scientific and Statistical Computational Core, NIMH, Bethesda (Rajendra); Department of Psychiatry and Behavioral Sciences, Institute for Early Life Adversity Research, University of Texas at Austin Dell Medical School, Austin (Nemeroff); Department of Psychology, Emory University, Atlanta (Craighead).
Jungho ChaDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, Craighead); Department of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Cha, Choi, Mayberg); Scientific and Statistical Computational Core, NIMH, Bethesda (Rajendra); Department of Psychiatry and Behavioral Sciences, Institute for Early Life Adversity Research, University of Texas at Austin Dell Medical School, Austin (Nemeroff); Department of Psychology, Emory University, Atlanta (Craighead).
Ki Sueng ChoiDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, Craighead); Department of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Cha, Choi, Mayberg); Scientific and Statistical Computational Core, NIMH, Bethesda (Rajendra); Department of Psychiatry and Behavioral Sciences, Institute for Early Life Adversity Research, University of Texas at Austin Dell Medical School, Austin (Nemeroff); Department of Psychology, Emory University, Atlanta (Craighead).
Justin K RajendraDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, Craighead); Department of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Cha, Choi, Mayberg); Scientific and Statistical Computational Core, NIMH, Bethesda (Rajendra); Department of Psychiatry and Behavioral Sciences, Institute for Early Life Adversity Research, University of Texas at Austin Dell Medical School, Austin (Nemeroff); Department of Psychology, Emory University, Atlanta (Craighead).
Charles B NemeroffDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, Craighead); Department of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Cha, Choi, Mayberg); Scientific and Statistical Computational Core, NIMH, Bethesda (Rajendra); Department of Psychiatry and Behavioral Sciences, Institute for Early Life Adversity Research, University of Texas at Austin Dell Medical School, Austin (Nemeroff); Department of Psychology, Emory University, Atlanta (Craighead).
W Edward CraigheadDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, Craighead); Department of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Cha, Choi, Mayberg); Scientific and Statistical Computational Core, NIMH, Bethesda (Rajendra); Department of Psychiatry and Behavioral Sciences, Institute for Early Life Adversity Research, University of Texas at Austin Dell Medical School, Austin (Nemeroff); Department of Psychology, Emory University, Atlanta (Craighead).
Helen S MaybergDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop, Craighead); Department of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York (Cha, Choi, Mayberg); Scientific and Statistical Computational Core, NIMH, Bethesda (Rajendra); Department of Psychiatry and Behavioral Sciences, Institute for Early Life Adversity Research, University of Texas at Austin Dell Medical School, Austin (Nemeroff); Department of Psychology, Emory University, Atlanta (Craighead).
Emory University · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 1985 to 2007
$21.3M
Special Scientific Procedures: Statistical Modeling CoreP50MH077083 · NIMH · EMORY UNIVERSITY · PI KUTNER, MICHAEL HENRY · 2006 to 2010
$9.3M
Predictors of Treatment Response Relapse and Recurrence in Major DepressionR01MH080880 · NIMH · EMORY UNIVERSITY · PI CRAIGHEAD, W. EDWARD · 2008 to 2012
$6.6M
Neural Correlates of Loss Aversion in Major DepressionK23MH086690 · NIMH · EMORY UNIVERSITY · PI DUNLOP, BOADIE W · 2009 to 2011
$521k
NCRR NIH HHS M01 RR000039NCRR NIH HHS UL1 RR025008NIMH NIH HHS K23 MH086690NIMH NIH HHS P50 MH077083NIMH NIH HHS R01 MH080880
6 · The paper itself

Abstract

objectiveThe authors sought to determine the shared and unique changes in brain resting-state functional connectivity (rsFC) between patients with major depressive disorder who achieved remission with cognitive-behavioral therapy (CBT) or with antidepressant medication.

methodsThe Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) trial randomized adults with treatment-naive major depressive disorder to 12 weeks of treatment with CBT (16 1-hour sessions) or medication (duloxetine 30-60 mg/day or escitalopram 10-20 mg/day). Resting-state functional MRI scans were performed at baseline and at week 12. The primary outcome was change in the whole-brain rsFC of four seeded brain networks among participants who achieved remission.

resultsOf the 131 completers with usable MRI data (74 female; mean age, 39.8 years), remission was achieved by 19 of 40 CBT-treated and 45 of 91 medication-treated patients. Three patterns of connectivity changes were observed. First, those who remitted with either treatment shared a pattern of reduction in rsFC between the subcallosal cingulate cortex and the motor cortex. Second, reciprocal rsFC changes were observed across multiple networks, primarily increases in CBT remitters and decreases in medication remitters. And third, in CBT remitters only, rsFC increased within the executive control network and between the executive control network and parietal attention regions.

conclusionsRemission from major depression via treatment with CBT or medication is associated with changes in rsFC that are mostly specific to the treatment modality, providing biological support for the clinical practice of switching between or combining these treatment approaches. Medication is associated with broadly inhibitory effects. In CBT remitters, the increase in rsFC strength between networks involved in cognitive control and attention provides biological support for the theorized mechanism of CBT. Reducing affective network connectivity with motor systems is a shared process important for remission with both CBT and medication.

Indexed as

Major Depressive DisorderAdultAntidepressive AgentsBrainDuloxetine HydrochlorideEscitalopramFemaleHumansMagnetic Resonance ImagingPsychotherapyAntidepressive AgentsDuloxetine HydrochlorideEscitalopramAntidepressantsBiological MarkersCognitive-Behavioral TherapyDepressive DisordersMajor Depressive DisorderPsychotherapy

Identifiers

PMID36651624
PMCPMC12212288
OpenAlexW4317212041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.